Category: thiazole

On April 10, 2014, Margathe, Jean-Francois; Iturrioz, Xavier; Alvear-Perez, Rodrigo; Marsol, Claire; Riche, Stephanie; Chabane, Hadjila; Tounsi, Nassera; Kuhry, Maxime; Heissler, Denis; Hibert, Marcel; Llorens-Cortes, Catherine; Bonnet, Dominique published an article.Safety of Methyl 2-(2-aminothiazol-4-yl)acetate The title of the article was Structure-Activity Relationship Studies toward the Discovery of Selective Apelin Receptor Agonists. And the article contained the following:

Apelin is the endogenous ligand for the previously orphaned G protein-coupled receptor APJ. Apelin and its receptor are widely distributed in the brain, heart, and vasculature, and are emerging as an important regulator of body fluid homeostasis and cardiovascular functions. To further progress in the pharmacol. and the physiol. role of the apelin receptor, the development of small, bioavailable agonists and antagonists of the apelin receptor, is crucial. In this context, E339-3D6 was described as the first nonpeptidic apelin receptor agonist. The authors show here that 1 is actually a mixture of polymethylated species, and they describe an alternative and versatile solid-phase approach that allows access to highly pure 27, the major component of 1. This approach was also applied to prepare a series of derivatives in order to identify the crucial structural determinants required for the ligand to maintain its affinity for the apelin receptor as well as its capacity to promote apelin receptor signaling and internalization. The study of the structure-activity relationships led to the identification of ligands 19, 21, and 38, which display an increased affinity compared to that of 27. The latter and 19 behave as full agonists with regard to cAMP production and apelin receptor internalization, whereas 21 is a biased agonist toward cAMP production Interestingly, the three ligands display a much higher stability in mouse plasma (T1/2 > 10 h) than the endogenous apelin-17 peptide 2 (T1/2 < 4 min). The experimental process involved the reaction of Methyl 2-(2-aminothiazol-4-yl)acetate(cas: 64987-16-2).Safety of Methyl 2-(2-aminothiazol-4-yl)acetate

The Article related to apelin receptor ligand fluorescent peptide solid phase preparation sar, Amino Acids, Peptides, and Proteins: Poly(Amino Acids) and Peptides and other aspects.Safety of Methyl 2-(2-aminothiazol-4-yl)acetate

Referemce:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica

On December 5, 2022, Odey, Joseph O.; Ubana, Emmanuel I.; Eko, Ishegbe J.; Jones, Okama O. published an article.Electric Literature of 2010-06-2 The title of the article was Synthesis, characterization and theoretical studies of the photovoltaic properties of novel bifunctional reactive disperse dyes based on aminothiazole derivatives. And the article contained the following:

This article comprises synthesis and characterization of two polyfunctional diazo reactive-disperse dyes with aminothiazole moiety for application in dye-sensitized solar cells (DSSC). The characterization techniques employed were Gas chromatog.-mass spectrometry (GC-MS), Fourier-transform IR spectroscopy (FT-IR), UV-visible spectroscopy (UV-vis), and NMR to determine the different functional groups, mol. connectivities and mol. weight of the various fragments of the synthesized dyes. Theor. D. Functional Theory (DFT) and Time-Dependent TD-DFT calculations were performed using B3LYP/6-311+g(d,p). It can be observed that the HOMO energy levels of the resp. dyes have lower values than I-/I3- redox couple level (around -4.80 eV) in the four different phases studied, which is crucial for the regeneration of the oxidized dye mol. and efficient charge separation Furthermore, the HOMO-LUMO energy gaps of DYES F and S are within the range 2.38-5.40 eV, where all LUMO-CB of TiO2 energy gap values are sufficient for generating enough driving force for effective electron injection. The promising results of Light-harvesting efficiency (LHE) (values ranging from 0.81 to 0.89 except for DYE S in chloroform phase where it has an unusual value of 0.21) and Open-circuit voltage (VOC) values gotten compared with other organic, and natural sensitizers were due to the better interaction between the carboxyl and carbonyl groups of aryl azo mol. joined to the thiazolyl nucleus and the surface of TiO2 permeable film. DYE S exhibits the lowest band gap (2.374eV), which designates the highest chem. activity of the two dyes. Results from the quantum theory of atoms-in-mols. indicate that DYES F and S exhibit addnl. stability due to their relatively high H-bond interactions as well as certain addnl. intra-at. bonds among the atoms of the investigated compounds The outcome of the Natural bond orbital (NBO) anal. suggests that the strongest charge transfer occurs in DYE S as compared to DYE F. The types and modes of excitations for the first five excited states of the synthesized dyes were observed from the results of the hole-electron excitation anal. First hyperpolarizability values of the dye F and dye S were determined to be 47.24 and 46.90 times the hyperpolarizability value of urea, demonstrating its excellent non-linear optical (NLO) response. The experimental process involved the reaction of 4-Phenylthiazol-2-amine(cas: 2010-06-2).Electric Literature of 2010-06-2

The Article related to bifunctional aminothiazole dye preparation dssc electron transfer nlo, Physical Organic Chemistry: Other Reactions, Processes, and Spectra and other aspects.Electric Literature of 2010-06-2

Referemce:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica

On November 20, 2008, Richter, Wolfgang published a patent.COA of Formula: C12H15NO3S The title of the patent was Preparation of tubulysine derivatives for treatment of cancer. And the patent contained the following:

The invention relates to novel cytotoxic peptides R1R2NCR3R4CONHCR5R6CONR7CR8R9-X-CHR10-A-CONHR11 [A is an optionally-substituted 5- or 6-membered heteroaryl ring; X is O, S, NR12, CR13R14, or CH2CR13R14; R1-R6, R8-R10, R12-R14 are independently H, optionally substituted alk(en)(yn)yl, aryl, heteroaryl, cycloalkyl, etc.; or two R groups form (hetero)cycloalkyl; R7 is alkyl, oxaalkyl, alkanoyl, CH2OCOPh, alkylaminoalkyl, hydroxyalkyl, etc.; R11 is -CH(CH2R15)(CH2)0-3CHR16R17, where R15 is optionally substituted aryl, heteroaryl, heterocycloalkyl,heteroalkylcycloalkyl, or heteroaralkyl;R16 is H, optionally alkyl, aryl, or heteroaryl;R17 is CO2H or ester, CONHNH2, OH, NH2, SH, or optionally substituted alkyl, cycloalkyl, heteroalkyl, orheterocycloalkyl] and their use for the treatment of cancer and other diseases. Thus, peptide I was prepared by a multistep procedure involving peptide coupling in solution Compounds of the invention show an activity against several cancer cell lines between 0.03 to 60 nM. The experimental process involved the reaction of Ethyl 2-(4-methylpent-2-enoyl)thiazole-4-carboxylate(cas: 944559-46-0).COA of Formula: C12H15NO3S

The Article related to peptide tubulysine derivative preparation treatment cancer, Amino Acids, Peptides, and Proteins: Poly(Amino Acids) and Peptides and other aspects.COA of Formula: C12H15NO3S

Referemce:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica

On May 8, 2013, Hazra, Dipak K.; Mukherjee, Monika; Mukherjee, Alok K. published an article.Reference of 2-(4-Aminophenyl)-6-methylbenzothiazole The title of the article was Ab initio powder structure analysis and theoretical study of two thiazole derivatives. And the article contained the following:

Crystal structures of 2-amino-5-methylthiazole (1) and 4-(6-methyl-2-benzothiazolyl) aniline (2) have been determined from laboratory X-ray powder diffraction data along with an anal. of the Hirshfeld surfaces and 2D-fingerprint plots, facilitating a comparison of intermol. interactions. The DFT optimized mol. geometries in (1) and (2) agree closely with those obtained from the crystallog. studies. An interplay of NH···N/S hydrogen bonds and C/NH···π interactions connects the mols. of (1) and (2) into two-dimensional framework. Hirshfeld surface anal. of (1) indicates that the H···H and H···π contacts can account for 56.9% of the Hirshfeld surface area, whereas the corresponding fraction in (2) is 80.5%. The experimental process involved the reaction of 2-(4-Aminophenyl)-6-methylbenzothiazole(cas: 92-36-4).Reference of 2-(4-Aminophenyl)-6-methylbenzothiazole

The Article related to ab initio powder structure analysis theory thiazole, Physical Organic Chemistry: Other Reactions, Processes, and Spectra and other aspects.Reference of 2-(4-Aminophenyl)-6-methylbenzothiazole

Referemce:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica

On May 31, 2007, Sani, Monica; Fossati, Giacomo; Huguenot, Florent; Zanda, Matteo published an article.Reference of Ethyl 2-(4-methylpent-2-enoyl)thiazole-4-carboxylate The title of the article was Total synthesis of tubulysins U and V. And the article contained the following:

A reliable and modular reaction sequence has been developed for the synthesis of the challenging tubulysin U and V (I, R = OAc, OH). This route allowed preparation of hundreds of milligrams of the stereochem. pure tetra-peptides, which are produced in small amounts by two different species of myxobacteria. This strategy made the full biol. evaluation of the tubulysins and their analogs possible. The experimental process involved the reaction of Ethyl 2-(4-methylpent-2-enoyl)thiazole-4-carboxylate(cas: 944559-46-0).Reference of Ethyl 2-(4-methylpent-2-enoyl)thiazole-4-carboxylate

The Article related to tubulysin asym preparation, Amino Acids, Peptides, and Proteins: Poly(Amino Acids) and Peptides and other aspects.Reference of Ethyl 2-(4-methylpent-2-enoyl)thiazole-4-carboxylate

Referemce:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica

On October 15, 2003, Puetz, Claudia; Sundermann, Bernd; Sundermann, Corinna; Ijzermann, Adriaan Pieter; Tromp, Reynier; Von Frijtag, Drabbe Kuenzel Jacobien published a patent.Electric Literature of 19989-66-3 The title of the patent was Preparation of analogs of nitrobenzylthioinosine for the treatment of pain, epilepsy, and other CNS-related disorders. And the patent contained the following:

This invention relates to new nucleoside analogs I, wherein or derivatives of nitrobenzylthioinosine, use of these new analogs of nitrobenzylthioinosine for the treatment of pain and various other diseases as well as pharmaceuticals comprising at least on new analog of nitrobenzylthioinosine. The derivatives of nitrobenzylthioinosine according to the invention are surprisingly effective in the treatment of pain and in other indications. Therefore a further embodiment of the invention comprises the use of a derivatives of nitrobenzylthioinosine according to the invention for the treatment of pain, especially acute, chronic and/or neuropathic pain. Treatment using derivatives of nitrobenzylthioinosine according to the invention especially for the treatment of pain, especially acute, chronic and/or neuropathic pain; the treatment of epilepsy and other CNS-related disorders as well as for neuro-protection or cardio-protection. A further embodiment of the invention comprises the use of a derivatives of nitrobenzylthioinosine according to the invention for the treatment of epilepsy and other CNS-related disorders as well as for neuroprotection or cardio-protection. Thus, 2-[6-(benzo[c]iso-thiazol-5-ylmethylsulfanyl)-purin-9-yl]-5-hydroxymethyl-tetrahydro-furan-3,4-diol was prepared and tested for the treatment of pain, epilepsy, transport protein on human erythrocyte membranes (Ki > 1.5 nM), and other CNS-related disorders. The experimental process involved the reaction of Benzo[d]thiazol-6-ylmethanol(cas: 19989-66-3).Electric Literature of 19989-66-3

The Article related to human nitrobenzylthioinosine nucleoside preparation treatment pain epilepsy cns, Carbohydrates: Nucleosides and Nucleotides, Cobalamins, Riboflavin and other aspects.Electric Literature of 19989-66-3

Referemce:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica

On September 1, 2009, Murray, Anthony; Lau, Jesper; Vedso, Per; Kristiansen, Marit; Jeppesen, Lone published a patent.SDS of cas: 859522-19-3 The title of the patent was Preparation of dicycloalkyl thiazolyl ureas as glucokinase activators. And the patent contained the following:

Title compounds represented by the formula R1R2NCONHA [wherein R1 = (un)substituted cyclohexyl; R2 = cyclohexyl; A = (un)substituted thiazolyl; and pharmaceutically acceptable salts, optical isomers or tautomers thereof] were prepared as glucokinase activators. For example, reaction of 2-aminothiazole with dicyclopentylamine and carbonyldiimidazole gave I. The glucose sensitivity of the title compounds are measured at a compound concentration of 10 μM and at glucose concentrations of 5 and 15 mM. The title compounds are useful as activators of glucokinase for the treatment of various diseases such as diabetes (no data). The experimental process involved the reaction of Ethyl 2-((2-aminothiazol-5-yl)thio)acetate(cas: 859522-19-3).SDS of cas: 859522-19-3

The Article related to dicycloalkyl thiazolyl urea preparation glucokinase activator, Heterocyclic Compounds (More Than One Hetero Atom): Thiazoles, Isothiazoles and other aspects.SDS of cas: 859522-19-3

Referemce:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica

On January 18, 2007, Murray, Anthony; Lau, Jesper; Vedsoe, Per; Kristiansen, Marit; Jeppesen, Lone published a patent.Related Products of 859522-19-3 The title of the patent was Preparation of dicycloalkyl thiazolyl ureas as glucokinase activators. And the patent contained the following:

Title compounds represented by the formula R1R2NCONHA [wherein R1 = (un)substituted cyclohexyl; R2 = cyclohexyl; A = (un)substituted thiazolyl; and pharmaceutically acceptable salts, optical isomers or tautomers thereof] were prepared as glucokinase activators. For example, reaction of 2-aminothiazole with dicyclopentylamine and carbonyldiimidazole gave I. The glucose sensitivity of the title compounds are measured at a compound concentration of 10 μM and at glucose concentrations of 5 and 15 mM. The title compounds are useful as activators of glucokinase for the treatment of diabetes (no data). The experimental process involved the reaction of Ethyl 2-((2-aminothiazol-5-yl)thio)acetate(cas: 859522-19-3).Related Products of 859522-19-3

The Article related to dicycloalkyl thiazolyl urea preparation glucokinase activator, Heterocyclic Compounds (More Than One Hetero Atom): Thiazoles, Isothiazoles and other aspects.Related Products of 859522-19-3

Referemce:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica

On January 18, 2007, Lau, Jesper; Murray, Anthony; Vedsoe, Per; Kristiansen, Marit; Jeppesen, Lone published a patent.Category: thiazole The title of the patent was Preparation of cyclohexyl thiazolyl ureas as glucokinase activators. And the patent contained the following:

Title compounds represented by the formula R1R2NCONHA [wherein R1 = (cycloalkyl)alkyl, cycloalkyl, heterocyclyl, etc.; R2 = (cyclo)alkyl, cycloalkenyl, heterocyclyl, etc.; A = (un)substituted heteroaryl; and pharmaceutically acceptable salts, optical isomers or tautomers thereof] were prepared as glucokinase activators. For example, reductive condensation of phenethylamine with cyclohexanone, followed by coupling reaction with Et (2-aminothiazol-5-ylsulfanyl)acetate in the presence of 1,1′-carbonyldiimidazole and hydrolysis, gave I. The glucose sensitivity of the title compounds are measured at a compound concentration of 10 μM and at glucose concentrations of 5 and 15 mM. The title compounds are useful as activators of glucokinase for the treatment of various diseases, e.g. for the treatment of type 2 diabetes (no data). The experimental process involved the reaction of Ethyl 2-((2-aminothiazol-5-yl)thio)acetate(cas: 859522-19-3).Category: thiazole

The Article related to cyclohexyl thiazolyl urea preparation glucokinase activator, Heterocyclic Compounds (More Than One Hetero Atom): Thiazoles, Isothiazoles and other aspects.Category: thiazole

Referemce:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica

On November 8, 2007, Murray, Anthony; Lau, Jesper; Jeppesen, Lone; Vedsoe, Per published a patent.Related Products of 859522-19-3 The title of the patent was Preparation of thiazolyl benzamides as glucokinase activators. And the patent contained the following:

Title compounds [I; m = 0-2; n = 0-4; R1 = OH, hydroxyalkyl, fluoroalkyl, Cll, F, Br, iodo, alkyl, alkenyl, alkynyl, amino, cyano, Ph, (substituted) heterocyclyl, etc.; R2 = YX; X = OZ, OZOZ, CO2Z, SZ, SOZ, SO2Z, etc.; Z, Z1 = bond, alkenylene, etc.; Y = (substituted) QZ1, etc.; Q = aryl, heterocyclyl, cycloalkyl; B = substituted 5-10 membered heterocyclyl], were prepared as glucokinase activators (no data). Thus, title compound Me [2-(3-isopropoxy-5-phenoxybenzoylamino)thiaol-5-ylsulfanyl]acetate was prepared in 4 steps from Me 3-isopropoxy-5-hydroxybenzoate, phenylboronic acid, 5-bromo-2-aminothiazole, 3-isopropoxy-5-phenoxybenzoic acid, and Me mercaptoacetate. The experimental process involved the reaction of Ethyl 2-((2-aminothiazol-5-yl)thio)acetate(cas: 859522-19-3).Related Products of 859522-19-3

The Article related to thiazolyl benzamide preparation glucokinase activator, Heterocyclic Compounds (More Than One Hetero Atom): Thiazoles, Isothiazoles and other aspects.Related Products of 859522-19-3

Referemce:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica